Anti-virals with Dr. San Luis

Question 1

This is a saturated 22-carbon aliphatic alcohol that inhibits fusion between the host cell plasma membrane and the HSV envelope, thereby preventing viral entry into cells and subsequent viral replication.

Answer 1

Docosanol

Question 2

The most common adverse effect of intravenous ganciclovir treatment is ___________, which although reversible may be dose-limiting.

Answer 2

myelosuppression

Question 3

This is an inorganic pyrophosphate analog that inhibits herpesvirus DNA polymerase, RNA polymerase, and HIV reverse transcriptase directly without requiring activation by phosphorylation.

Answer 3

Foscarnet

Question 4

M2 ion channel blockers

Answer 4

Adamantanes:
Amantadine and Rimantadine

Question 5

Neuraminidase inhibitors

Answer 5

Oseltamivir and Zanamivir

Question 6

Recommended by the WHO for primary treatment and prevention of human H5N1 disease

Answer 6

Oseltamivir

Question 7

An antiviral agent that was by chance found to have relatively weak antiparkinsonism properties since it is an antagonist of the NMDA-type glutamate receptor, suggesting an antidyskinetic effect.

Answer 7

Amantadine

Question 8

This is a cutaneous physical sign characterized by transient or persistent, blotchy, reddish-blue to purple, net-like cyanotic pattern that sometimes occur in patients taking amantadine.

Answer 8

Livedo reticularis

Question 9

Overdosage of amantadine may produce:

Answer 9

acute toxic psychosis

Question 10

This is the oral prodrug of beta-D-N4-hydroxycytidine (NHC), a ribonucleoside that has shown antiviral activity against SARS-CoV-2

Answer 10

Molnupiravir

Question 11

Drugs for HBV

Answer 11

Lamivudine
Adefovir dipivoxil
Tenofovir
Entecavir

LATE

Question 12

This is a nucleotide analog of adenosine in use as an antiretroviral agent, has potent activity against HBV

Answer 12

Tenofovir disoproxil

Question 13

Drug of choice for HCV

Answer 13

Sofosbuvir

Question 14

This is used in combination with sofosbuvir for treatment of HCV genotypes 1, 2, and 3.

Answer 14

Daclatasvir

Question 15

As a potent inhibitor of CYP3A4, this drug results in many potential drug interactions. However, this characteristic has been used to great advantage when this drug is administered in low doses (100–200 mg twice daily) in combination with any of the other PI agents, to permit lower or less frequent dosing (or both) with greater tolerability as well as the potential for greater efficacy against resistant virus.

Answer 15

Ritonavir

Question 16

This is a synthetic 36-amino-acid peptide fusion inhibitor that blocks HIV entry into the cell

Answer 16

Enfuvirtide

Question 17

This drug is approved for use in combination with other antiretroviral agents in adult patients infected only with CCR5-tropic HIV-1. It binds specifically and selectively to the host protein CCR5, one of two chemokine receptors necessary for entrance of HIV into CD4+ cells.

Answer 17

Maraviroc

Question 18

Drug that inhibits SARS-cov-2 viral RNA-dependent RNA-polymerase, leading to lethal mutagenesis

Answer 18

Molnupiravir

Question 19

New monoclonal antibodies directed against SARS-CoV-2 spike protein, blocking viral attachment and entry

Answer 19

Casirivimab/Imdevimab (REGEN-COV)

Question 20

This is a cytosine nucleotide analog with in vitro activity against CMV

Answer 20

Cidofovir

Question 21

TAMIFLU

Answer 21

Oseltamivir phosphate

Question 22

The neuraminidase inhibitors are analogs of:

Answer 22

sialic acid

Question 23

This is an immune response modifier shown to be effective in the topical treatment of external genital and perianal warts (i.e., condyloma acuminatum)

Answer 23

Imiquimod